Additionally, we observed an approximately 2-fold occurrence of PALB2 pathogenic variants in breast cancer patients aged ≤ 30 years compared to those aged 31-40 years (1.3% vs 0.68%), however, the difference was not statistically significant (p = 0.398). This evidence concerns the gene PALB2 and breast carcinoma.